Adalimumab biosimilar - Zydus Cadila

Drug Profile

Adalimumab biosimilar - Zydus Cadila

Alternative Names: Exemptia; ZRC-3197

Latest Information Update: 11 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zydus Cadila
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 09 Dec 2014 Launched for Ankylosing spondylitis in India (SC) - First global launch
  • 09 Dec 2014 Launched for Juvenile rheumatoid arthritis in India (SC) - First global launch
  • 09 Dec 2014 Launched for Psoriatic arthritis in India (SC) - First global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top